<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38164695</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Modeling undetected poliovirus circulation following the 2022 outbreak in the United States.</ArticleTitle><Pagination><StartPage>186</StartPage><EndPage>195</EndPage><MedlinePgn>186-195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2023.2299401</ELocationID><Abstract><AbstractText Label="BACKGROUND">New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS">Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).</AbstractText><AbstractText Label="RESULTS">With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.</AbstractText><AbstractText Label="CONCLUSIONS">In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routh</LastName><ForeName>Janell A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Eli S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Office of Public Health, New York State Department of Health, Albany, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, State University of New York at Albany, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>I Ravi</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Office of Public Health, New York State Department of Health, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucker</LastName><ForeName>Jane R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>New York City Department of Health and Mental Hygiene, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langdon-Embry</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>New York City Department of Health and Mental Hygiene, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc, Orlando, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, Syracuse University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062065">Wastewater</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062065" MajorTopicYN="N">Wastewater</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">outbreak response</Keyword></KeywordList><CoiStatement>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>2</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38164695</ArticleId><ArticleId IdType="mid">NIHMS2009839</ArticleId><ArticleId IdType="pmc">PMC11284832</ArticleId><ArticleId IdType="doi">10.1080/14760584.2023.2299401</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Aug 19;71(33):1065–1068. doi: 10.15585/mmwr.mm7133e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson AB, Lang D, Alazawi MA, et al. Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio case - New York, March 9-October 11, 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 4;71(44):1418–1424. doi: 10.15585/mmwr.mm7144e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e2</ArticleId><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Routh JA, et al. Modeling poliovirus transmission and responses in New York State. J Infect Dis. 2023 Aug 19. doi: 10.1093/infdis/jiad355</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad355</ArticleId><ArticleId IdType="pmc">PMC11284859</ArticleId><ArticleId IdType="pubmed">37596838</ArticleId></ArticleIdList></Reference><Reference><Citation>Seither R, Yusuf OB, Dramann D, et al. Coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten - United States, 2022–23 school year. MMWR Morb Mortal Wkly Rep. 2023 Nov 10;72 (45):1217–1224. doi: 10.15585/mmwr.mm7245a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7245a2</ArticleId><ArticleId IdType="pmc">PMC10651323</ArticleId><ArticleId IdType="pubmed">37943705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman NS, Bar-Or I, Sofer D, et al. Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill. 2022. Sep;27(37): doi: 10.2807/1560-7917.ES.2022.27.37.2200694</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.37.2200694</ArticleId><ArticleId IdType="pmc">PMC9479469</ArticleId><ArticleId IdType="pubmed">36111556</ArticleId></ArticleIdList></Reference><Reference><Citation>Klapsa D, Wilton T, Zealand A, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. 2022 Oct 29;400 (10362):1531–1538. doi: 10.1016/S0140-6736(22)01804-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01804-9</ArticleId><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="pubmed">36243024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization. Epidemiological update detection of poliovirus in wastewater: considerations for the region of the Americas 2022. 2022 Dec 30 [cited 2022 Dec 31]. Available from: https://www.paho.org/en/documents/epidemiological-update-detection-poliovirus-wastewater</Citation></Reference><Reference><Citation>GPEI. Circulating vaccine-derived poliovirus: World Health Organization - global polio eradication initiative; 2023 Apr 25 [cited 2023 May 1]. Available from: https://polioeradication.org/polio-today/polio-prevention/the-virus/vaccine-derived-polio-viruses/</Citation></Reference><Reference><Citation>Thompson KM, Wallace GS, Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep. 2012. Jan;127(1):23–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234395</ArticleId><ArticleId IdType="pubmed">22298920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015 Jun 1;211(11):1800–12. doi: 10.1093/infdis/jiu674</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu674</ArticleId><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>National notifiable diseases surveillance system (NNDSS). Poliomyelitis, paralytic - 2010 case definition: US Centers for Disease Control and Prevention (CDC); 2010.  [updated
April 16, 2021; cited 2023 Jun 30]. Available from: https://ndc.services.cdc.gov/case-definitions/poliomyelitis-paralytic-2010/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Considerations for wastewater testing for poliovirus in the United States: national center for immunization and respiratory diseases, division of viral diseases; 2023 May 12 [cited 2023 Aug 4]. Available from: https://www.cdc.gov/polio/us/lab-testing/wastewater-testing/considerations.html</Citation></Reference><Reference><Citation>Eichner M, Hadeler KP. Deterministic models for the eradication of poliomyelitis: vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Math Biosci. 1995. Jun;127(2):149–66. doi: 10.1016/0025-5564(94)00046-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0025-5564(94)00046-3</ArticleId><ArticleId IdType="pubmed">7795316</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol. 1996;143(8):816–822. doi: 10.1093/oxfordjournals.aje.a008820</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a008820</ArticleId><ArticleId IdType="pubmed">8610692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. Am J Epidemiol. 2012 May 1;175 (9):936–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">22459121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, et al. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. BMC Infect Dis. 2015;15(1):66. doi: 10.1186/s12879-015-0791-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-0791-5</ArticleId><ArticleId IdType="pmc">PMC4344758</ArticleId><ArticleId IdType="pubmed">25886823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, et al. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. Risk Anal. 2019;39(2):402–413. doi: 10.1111/risa.13214</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13214</ArticleId><ArticleId IdType="pmc">PMC7842182</ArticleId><ArticleId IdType="pubmed">30296340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation. Risk Anal. 2019;39(2):414–425. doi: 10.1111/risa.13193</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13193</ArticleId><ArticleId IdType="pmc">PMC7857156</ArticleId><ArticleId IdType="pubmed">30239023</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, Thompson KM. Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission. BMJ Open. 2019;9(1):e023938. doi: 10.1136/bmjopen-2018-023938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-023938</ArticleId><ArticleId IdType="pmc">PMC6340450</ArticleId><ArticleId IdType="pubmed">30647038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in northeast Nigeria. Risk Anal. 2021;41(2):303–311. doi: 10.1111/risa.13486</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13486</ArticleId><ArticleId IdType="pmc">PMC7814396</ArticleId><ArticleId IdType="pubmed">32348634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, Thompson KM. Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. Risk Anal. 2023. Apr;43(4):677–685. doi: 10.1111/risa.13982</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13982</ArticleId><ArticleId IdType="pmc">PMC9780400</ArticleId><ArticleId IdType="pubmed">35739067</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, et al. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. Food Environ Virol. 2017;9(4):361–382. doi: 10.1007/s12560-017-9314-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12560-017-9314-4</ArticleId><ArticleId IdType="pmc">PMC7879701</ArticleId><ArticleId IdType="pubmed">28687986</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Kew OM, de Gourville EM, et al. The global polio laboratory network as a platform for the viral vaccine-preventable and emerging diseases laboratory networks. J Infect Dis. 2017 Jul 1;216 (suppl_1):S299–S307. doi: 10.1093/infdis/jix092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix092</ArticleId><ArticleId IdType="pmc">PMC5853949</ArticleId><ArticleId IdType="pubmed">28838192</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangermann RH, Lamoureux C, Tallis G, et al. The critical role of acute flaccid paralysis surveillance in the global polio eradication initiative. Int Health. 2017 May 1;9(3):156–163. doi: 10.1093/inthealth/ihx016</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/inthealth/ihx016</ArticleId><ArticleId IdType="pubmed">28582560</ArticleId></ArticleIdList></Reference><Reference><Citation>National notifiable diseases surveillance system (NNDSS). Acute flaccid myelitis (AFM) - 2022 case definition: US Centers for Disease Control and Prevention (CDC); 2022. 
updated
August 30, 2021 [cited 2023 Jun 30]. Available from: https://ndc.services.cdc.gov/case-definitions/acute-flaccid-myelitis-2022/</Citation></Reference><Reference><Citation>Neyra M, Hill DT, Bennett LJ, et al. Establishing a statewide wastewater surveillance system in response to the COVID-19 pandemic: a reliable model for continuous and emerging public health threats. J Public Health Manag Pract. 2023;29(6):854–862. doi: 10.1097/PHH.0000000000001797</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHH.0000000000001797</ArticleId><ArticleId IdType="pmc">PMC10549888</ArticleId><ArticleId IdType="pubmed">37566797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder ML, Middleton F, Larsen DA, et al. Co-quantification of crAssphage increases confidence in wastewater-based epidemiology for SARS-CoV-2 in low prevalence areas. Water Res X. 2021 May 1;11:100100. doi: 10.1016/j.wroa.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wroa.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8021452</ArticleId><ArticleId IdType="pubmed">33842875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill DT, Larsen DA. Using geographic information systems to link population estimates to wastewater surveillance data in New York State, USA. PLOS Glob Public Health. 2023;3(1):e0001062. doi: 10.1371/journal.pgph.0001062</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0001062</ArticleId><ArticleId IdType="pmc">PMC10021809</ArticleId><ArticleId IdType="pubmed">36962986</ArticleId></ArticleIdList></Reference><Reference><Citation>NYS Department of Health. The New York State Wastewater Surveillance Network: New York State Department of Health; 2023.  [cited 2023 Jul 24]. Available from: https://coronavirus.health.ny.gov/covid-19-wastewater-surveillance</Citation></Reference><Reference><Citation>U.S. Census Bureau. U.S. Census Bureau Population Estimates Data Tables
2022.  [cited 2022 Nov 23]. Available from: https://www2.census.gov/programs-surveys/popest/datasets/2020-2021/counties/asrh/cc-est2021-all.csv</Citation></Reference><Reference><Citation>Sun H, Harrington C, Gerloff N, et al. Validation of a redesigned pan-poliovirus assay and real-time PCR platforms for the global poliovirus laboratory network. PLoS One. 2021;16(8):e0255795. doi: 10.1371/journal.pone.0255795</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255795</ArticleId><ArticleId IdType="pmc">PMC8345876</ArticleId><ArticleId IdType="pubmed">34358268</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz CF, Kovacs SD, Mach O. Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks. Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A113–A121. doi: 10.1016/j.vaccine.2022.03.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.027</ArticleId><ArticleId IdType="pmc">PMC10389290</ArticleId><ArticleId IdType="pubmed">35365341</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976–1995. J Infect Dis. 1997. Feb;175(Suppl 1): S165–72. doi: 10.1093/infdis/175.Supplement_1.S165</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/175.Supplement_1.S165</ArticleId><ArticleId IdType="pubmed">9203711</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. Eurosurveillance. 2013;18(38):20586. doi: 10.2807/1560-7917.ES2013.18.38.20586</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2013.18.38.20586</ArticleId><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Qi Q, Zhang Y, et al. Analysis of a sabin-strain inactivated poliovirus vaccine response to a circulating type 2 vaccine-derived poliovirus event in Sichuan Province, China 2019–2021. JAMA Netw Open. 2023 Jan 3;6(1):e2249710. doi: 10.1001/jamanetworkopen.2022.49710</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.49710</ArticleId><ArticleId IdType="pmc">PMC9856606</ArticleId><ArticleId IdType="pubmed">36602797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzoev A, Macklin GR, Zhang Y, et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob Health. 2022. Dec;10(12):e1807–e1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="pubmed">36400086</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. Guidance. Polio immunisation response in London 2022 to 2023: information for healthcare practitioners
2023. 
2023 May 24 [cited 2023 Jul 25]. Available from: https://www.gov.uk/government/publications/inactivated-polio-vaccine-ipv-booster-information-for-healthcare-practitioners/polio-immunisation-response-in-london-2022-to-2023-information-for-healthcare-practitioners</Citation></Reference><Reference><Citation>World Health Organization. Statement of the thirty-fifth Polio IHR Emergency Committee Geneva Switzerland: World Health Organization; 2023 May 12 [cited 2023 Aug 4]. Available from: https://www.who.int/news/item/12-05-2023-statement-of-the-thirty-fifth-polio-ihr-emergency-committee</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>